PL2467153T3 - Zastosowanie mimotopów epitopów alfa-synukleiny do leczenia chorób z ciałami Lewy'ego - Google Patents

Zastosowanie mimotopów epitopów alfa-synukleiny do leczenia chorób z ciałami Lewy'ego

Info

Publication number
PL2467153T3
PL2467153T3 PL10747562.6T PL10747562T PL2467153T3 PL 2467153 T3 PL2467153 T3 PL 2467153T3 PL 10747562 T PL10747562 T PL 10747562T PL 2467153 T3 PL2467153 T3 PL 2467153T3
Authority
PL
Poland
Prior art keywords
mimotopes
alpha
lewy body
body diseases
treating lewy
Prior art date
Application number
PL10747562.6T
Other languages
English (en)
Inventor
Markus Mandler
Harald Weninger
Radmila Santic
Christian Lahsnig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2467153T3 publication Critical patent/PL2467153T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PL10747562.6T 2009-08-21 2010-08-20 Zastosowanie mimotopów epitopów alfa-synukleiny do leczenia chorób z ciałami Lewy'ego PL2467153T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0132409A AT508638B1 (de) 2009-08-21 2009-08-21 Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien

Publications (1)

Publication Number Publication Date
PL2467153T3 true PL2467153T3 (pl) 2016-09-30

Family

ID=42940852

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10747562.6T PL2467153T3 (pl) 2009-08-21 2010-08-20 Zastosowanie mimotopów epitopów alfa-synukleiny do leczenia chorób z ciałami Lewy'ego

Country Status (21)

Country Link
US (1) US8828942B2 (pl)
EP (1) EP2467153B1 (pl)
JP (2) JP2013502379A (pl)
KR (2) KR20140141651A (pl)
CN (1) CN102596224B (pl)
AT (1) AT508638B1 (pl)
AU (1) AU2010283948B2 (pl)
BR (1) BR112012003800A2 (pl)
CA (1) CA2771429A1 (pl)
CY (1) CY1117582T1 (pl)
DK (1) DK2467153T3 (pl)
ES (1) ES2573662T3 (pl)
HR (1) HRP20160594T1 (pl)
HU (1) HUE027563T2 (pl)
IL (1) IL218207A0 (pl)
MX (1) MX2012002153A (pl)
PL (1) PL2467153T3 (pl)
PT (1) PT2467153E (pl)
RU (1) RU2532351C2 (pl)
SI (1) SI2467153T1 (pl)
WO (1) WO2011020133A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2496341T3 (es) 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
CA2924268C (en) 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
KR102857456B1 (ko) 2015-11-03 2025-09-08 에이씨 이뮨 에스에이 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법
KR101726549B1 (ko) 2016-06-29 2017-04-12 정상문 모바일 실시간 시뮬레이션 게임에서의 터치 조작 방식
KR102087494B1 (ko) 2018-03-15 2020-03-10 정상문 모바일 실시간 시뮬레이션 게임에서 객체를 표시하는 방법
AU2019406749A1 (en) 2018-12-20 2021-05-27 Saiba AG Virus-like particles of CMV modified by fusion
JP7849854B2 (ja) * 2020-07-29 2026-04-22 国立大学法人東北大学 シヌクレイノパチーを予防又は治療するために使用されるペプチド
IL300364A (en) 2020-08-04 2023-04-01 Ac Immune Sa immunogenic substances
US20240189407A1 (en) 2021-04-12 2024-06-13 Saiba AG Modified virus-like particles of bacteriophage ap205
JPWO2022265091A1 (pl) * 2021-06-18 2022-12-22
US20250152684A1 (en) 2022-02-09 2025-05-15 Ac Immune Sa Anti-Alpha-Synuclein Therapeutic Vaccines
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
US20250186596A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007325595A (ja) * 2000-12-22 2007-12-20 Locomogene Inc 滑膜細胞タンパク質
CA2466841A1 (en) * 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
PL1633189T3 (pl) * 2003-05-19 2017-12-29 Prothena Biosciences Limited Skrócone fragmenty alfa-synukleiny w chorobie z ciałami lewy'ego
JPWO2004113535A1 (ja) 2003-06-22 2007-09-20 早出　広司 凝集抑制作用を有するシヌクレイン変異体
WO2006004066A1 (ja) * 2004-07-02 2006-01-12 Locomogene, Inc. S1-5を含有するタンパク質製剤
ZA200701531B (en) 2004-08-09 2009-03-25 Elan Pharm Inc Prevention and treatment of synucleinopathic and amyloidogenic disease
MX2007001679A (es) * 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
SG172617A1 (en) * 2005-12-12 2011-07-28 Ac Immune Sa Therapeutic vaccine
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies

Also Published As

Publication number Publication date
KR101517447B1 (ko) 2015-05-28
KR20140141651A (ko) 2014-12-10
CN102596224A (zh) 2012-07-18
AT508638B1 (de) 2011-08-15
ES2573662T3 (es) 2016-06-09
WO2011020133A1 (en) 2011-02-24
JP2013502379A (ja) 2013-01-24
JP2015038078A (ja) 2015-02-26
EP2467153A1 (en) 2012-06-27
RU2012110582A (ru) 2013-09-27
CA2771429A1 (en) 2011-02-24
CY1117582T1 (el) 2017-04-26
US8828942B2 (en) 2014-09-09
DK2467153T3 (en) 2016-06-06
EP2467153B1 (en) 2016-03-02
KR20120059562A (ko) 2012-06-08
JP5901714B2 (ja) 2016-04-13
CN102596224B (zh) 2015-12-09
BR112012003800A2 (pt) 2016-11-22
AT508638A1 (de) 2011-03-15
RU2532351C2 (ru) 2014-11-10
IL218207A0 (en) 2012-04-30
HUE027563T2 (en) 2016-10-28
US20120156234A1 (en) 2012-06-21
AU2010283948B2 (en) 2015-01-22
MX2012002153A (es) 2012-03-14
SI2467153T1 (sl) 2016-07-29
HRP20160594T1 (hr) 2016-07-29
AU2010283948A1 (en) 2012-03-29
HK1170658A1 (zh) 2013-03-08
PT2467153E (pt) 2016-06-08

Similar Documents

Publication Publication Date Title
IL218207A0 (en) Use of mimotopes of alpha-synuclein epitopes for treating lewy body diseases
HRP20181512T1 (hr) Mimotopi od alfa-sinukleina i njihova cjepiva za liječenje neurodegenerativnih poremećaja
IL216509A0 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
EP2425875A4 (en) MASK COVER
EP2427250A4 (en) THERAPEUTIC BODY STRAP
IL219974A0 (en) Therapeutic compounds and related methods of use
MX2018014044A (es) Anticuerpos humanizados que reconocen alfa-sinucleina.
IL217777A0 (en) Methods for treatment of pain
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
PT2435825E (pt) Métodos para o tratamento de doenças
GB0902040D0 (en) Composition for treatment of skin
IL241253A0 (en) Peptides for the treatment of neurodegenerative diseases
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
PL2735316T3 (pl) Nowe podejścia terapeutyczne do leczenia stanów zapalnych układu nerwowego
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
EP2512484A4 (en) METHODS FOR THE TREATMENT OF SPEECH DISORDERS
GB0905954D0 (en) Treatment of exacerbations of asthma
GB0908666D0 (en) Treatment of proteostatic disease
TWM386004U (en) Improved structure of incense body
TWM372652U (en) Umbrella capable of covering body
GB0901727D0 (en) The treatment of ophthalmic diseases
GB0906222D0 (en) Methods for screening of therapeutic agents